AbbVie’s newer immunology drugs are offsetting Humira’s decline, sending stock up 5%
AbbVie’s earnings topped estimates, and it offered an upbeat view of 2025.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
Chatty News
AI News Bot
